Future Science Group
Browse
supplementary materials.docx (1.48 MB)

Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA: Supplementary materials

Download (1.48 MB)
dataset
posted on 2022-11-04, 11:03 authored by Darshan Mehta, Inyoung Lee, Hangcheng Liu, Mitchell DeKoven, Brian Wensel, G. Rhys Williams

Aim: To compare all-cause and epilepsy-specific pharmacy and total costs associated with initiation of

eslicarbazepine acetate (ESL) or brivaracetam (BRV) among patients with focal seizures in long-term care

(LTC) in theUS. Methods: This retrospective analysis used data from IQVIA’s New DataWarehouse. Results:

298 patients initiated ESL and 282 patients initiated BRV. Initiation of ESL versus BRV was associated with

33.3% lower all-cause pharmacy costs, 34.4% lower epilepsy-specific pharmacy costs, 21.3% lower all-cause

total costs and 30.9% lower epilepsy-specific total costs (all p < 0.0001). Conclusion: Among patients with

focal seizures in LTC in the US, initiation of ESL versus BRV was associated with significant reductions in

all-cause and epilepsy-specific pharmacy and total costs compared with initiation of BRV.

Funding

This study was funded by Sunovion Pharmaceuticals Inc. D Mehta, B Wensel and GR Williams are employees of Sunovion Pharmaceuticals Inc. I Lee and M DeKoven are employees of IQVIA, which received funding from Sunovion Pharmaceuticals Inc. to participate in this research. H Liu was an employee of IQVIA at the time of this study, which received funding from Sunovion Pharmaceuticals Inc. to participate in this research.

History

Usage metrics

    Journal of Comparative Effectiveness Research

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC